Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
View Patent ↗Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.
1. A method of treating edema in a subject in need thereof, comprising:
identifying a subject having edema; and
administering to said subject an isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs, wherein greater than 5% of said population of adipose-derived cells express FLT-4.
2. The method of claim 1 , wherein the edema is lymphedema.
3. The method of claim 1 , wherein said subject has a wound.
4. The method of claim 3 , wherein said wound is a burn.
5. The method of claim 3 , wherein said wound is a skin wound following grafting.
6. The method of claim 3 , wherein said wound is a radiation wound.
7. The method of claim 1 , wherein said isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs is administered by injection into a lymph node.
8. The method of claim 1 , wherein said isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs is administered by injection into lymphatic vessels.
9. The method of claim 1 , wherein said isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs is administered by injection into tissue space.
10. The method of claim 1 , wherein greater than 5% of said population of adipose-derived cells also express CD45.
11. The method of claim 1 , wherein greater than 5% of said population of adipose-derived cells also express CD34.
12. The method of claim 1 , wherein greater than 5% of said population of adipose-derived cells also express CD14.
13. The method of claim 1 , wherein said isolated population of adipose-derived cells is mixed with an additive prior to administering the adipose-derived cells to the subject.
14. The method of claim 13 , wherein said additive is selected from the group consisting of an anti-apoptosis agent, a growth factor, a tissue graft, a portion of unprocessed adipose tissue, a population of adipose-derived stem cells, a population of adipose-derived endothelial cells, population of adipose-derived progenitor cells, a cell differentiation factor.
15. The method of claim 1 , wherein said identification comprises examination of a tissue biopsy, fluorescence micorlymphangiography, computed tomography, X-ray lymphography, dual0site fluorescence angiography, isotope lymphography, laser-Doppler analysis, magnetic resonance imaging, ultrasonography, or any combination thereof.
16. The method of claim 1 , wherein said isolated population of adipose-derived cells is not cultured prior to providing the isolated population of adipose-derived cells to the subject.
17. The method of claim 1 , wherein said isolated population of adipose-derived cells is cultured in vitro prior to providing the isolated population of adipose-derived cells to the subject.
18. The method of claim 1 , wherein said isolated population of adipose-derived cells is obtained by processing adipose tissue in a cell processing device configured to maintain a closed pathway.
19. The method of claim 1 , further comprising analyzing said edema following the administration of said isolated population of adipose-derived cells.
20. The method of claim 1 , wherein the isolated population of adipose-derived cells comprising LECs and pre-LECs is cryopreserved.